Literature DB >> 28721898

Radiation Treatment Time and Overall Survival in Locally Advanced Non-small Cell Lung Cancer.

Matthew T McMillan1, Eric Ojerholm1, Vivek Verma2, Kristin A Higgins3, Sunil Singhal4, Jarrod D Predina4, Abigail T Berman1, Surbhi Grover1, Cliff G Robinson5, Charles B Simone6.   

Abstract

PURPOSE: Prolonged radiation treatment (RT) time (RTT) has been associated with worse survival in several malignancies. The present study investigated whether delays during RT are associated with overall survival (OS) in non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: The National Cancer Database was queried for patients with stage III NSCLC who had received definitive concurrent chemotherapy and fractionated RT to standard doses (59.4-70.0 Gy) and fractionation from 2004 to 2013. The RTT was classified as standard or prolonged for each treatment regimen according to the radiation dose and number of fractions. Cox proportional hazards models were used to evaluate the association between the following factors and OS: RTT, RT fractionation, demographic and pathologic factors, and chemotherapeutic agents.
RESULTS: Of 14,154 patients, the RTT was prolonged in 6262 (44.2%). Factors associated with prolonged RTT included female sex (odds ratio [OR] 1.21, P<.0001), black race (OR 1.20, P=.001), nonprivate health insurance (OR 1.30, P<.0001), and lower income (<$63,000 annually, OR 1.20, P<.0001). The median OS was significantly worse for patients with prolonged RTT than that for those with standard RTT (18.6 vs 22.7 months, P<.0001). Furthermore, the OS worsened with each cumulative interval of delay (standard RTT vs prolonged 1-2 days, 20.5 months, P=.009; prolonged 3-5 days, 17.9 months, P<.0001; prolonged 6-9 days, 17.7 months, P<.0001; prolonged >9 days, 17.1 months, P<.0001). On multivariable analysis, prolonged RTT was independently associated with inferior OS (hazard ratio 1.21, P<.0001). Prolonged RTT as a continuous variable was also significantly associated with worse OS (hazard ratio 1.001, P=.0007).
CONCLUSIONS: Delays during RT appear to negatively affect survival for patients with locally advanced NSCLC. We have detailed the demographic and socioeconomic barriers influencing prolonged RTT as a method to address the health disparities in this regard. Cumulative interruptions of RT should be minimized.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28721898     DOI: 10.1016/j.ijrobp.2017.04.004

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  27 in total

1.  Factors predicting intolerance to definitive conventional radiotherapy in geriatric patients.

Authors:  Chai Hong Rim; Won Sup Yoon; Jung Ae Lee; Dae Sik Yang; Nam Kwon Lee; Young Je Park; Chul Yong Kim
Journal:  Strahlenther Onkol       Date:  2018-05-24       Impact factor: 3.621

2.  Dose-escalation of locally advanced non-small cell lung cancer with proton beam therapy.

Authors:  Vivek Verma; Joe Y Chang
Journal:  Transl Lung Cancer Res       Date:  2018-09

3.  Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy.

Authors:  Vivek Verma; Joe Y Chang
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Suggestions for radiation oncologists to overcome radiotherapy interruption in patients with nasopharyngeal cancer.

Authors:  Jung Ae Lee; Won Sup Yoon
Journal:  Ann Transl Med       Date:  2019-09

Review 5.  Proton therapy for small cell lung cancer.

Authors:  Vivek Verma; J Isabelle Choi; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2018-04

6.  Addition of chemotherapy to hypofractionated radiotherapy for glioblastoma: practice patterns, outcomes, and predictors of survival.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Neurooncol       Date:  2017-10-31       Impact factor: 4.130

7.  Pattern of care in radiotherapy at a University Hospital in Spain: the RENORT project.

Authors:  J López-Torrecilla; D González Sanchis; D Granero Cabañero; E García Miragall; P Almendros Blanco; A Hernandez Machancoses; L Brualla González; J Pastor Peidro; J C Gordo Partearroyo; J Rosello Ferrando
Journal:  Clin Transl Oncol       Date:  2021-02-14       Impact factor: 3.405

8.  Survival impact of prolonged postoperative radiation therapy for patients with glioblastoma treated with combined-modality therapy.

Authors:  Mehran B Yusuf; Jeremy Gaskins; Mark J Amsbaugh; Shiao Woo; Eric Burton
Journal:  Neurooncol Pract       Date:  2018-07-20

9.  Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-04

10.  Utilization of intensity modulated radiation therapy for anal cancer in the United States.

Authors:  Waqar Haque; Vivek Verma; E Brian Butler; Bin S Teh
Journal:  J Gastrointest Oncol       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.